vs
Orthofix Medical Inc.（OFIX）与TERADATA CORP（TDC）财务数据对比。点击上方公司名可切换其他公司
TERADATA CORP的季度营收约是Orthofix Medical Inc.的1.9倍（$421.0M vs $219.9M），TERADATA CORP净利率更高（8.8% vs -1.0%，领先9.8%），TERADATA CORP同比增速更快（2.9% vs 2.0%），TERADATA CORP自由现金流更多（$151.0M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -4.8%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Teradata是全球知名的企业级软件与数据分析服务商，提供云原生数据平台、高级分析工具及专业咨询服务，服务金融、零售、电信、医疗等行业的大型企业客户，助力客户整合海量数据，实现数据驱动的业务决策。
OFIX vs TDC — 直观对比
营收规模更大
TDC
是对方的1.9倍
$219.9M
营收增速更快
TDC
高出1.0%
2.0%
净利率更高
TDC
高出9.8%
-1.0%
自由现金流更多
TDC
多$134.2M
$16.8M
两年增速更快
OFIX
近两年复合增速
-4.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $421.0M |
| 净利润 | $-2.2M | $37.0M |
| 毛利率 | 71.1% | 60.8% |
| 营业利润率 | 0.2% | 12.8% |
| 净利率 | -1.0% | 8.8% |
| 营收同比 | 2.0% | 2.9% |
| 净利润同比 | 92.4% | 48.0% |
| 每股收益（稀释后） | $-0.05 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXTDC
| Q4 25 | $219.9M | $421.0M | ||
| Q3 25 | $205.6M | $416.0M | ||
| Q2 25 | $203.1M | $408.0M | ||
| Q1 25 | $193.6M | $418.0M | ||
| Q4 24 | $215.7M | $409.0M | ||
| Q3 24 | $196.6M | $440.0M | ||
| Q2 24 | $198.6M | $436.0M | ||
| Q1 24 | $188.6M | $465.0M |
净利润OFIXTDC
| Q4 25 | $-2.2M | $37.0M | ||
| Q3 25 | $-22.8M | $40.0M | ||
| Q2 25 | $-14.1M | $9.0M | ||
| Q1 25 | $-53.1M | $44.0M | ||
| Q4 24 | $-29.1M | $25.0M | ||
| Q3 24 | $-27.4M | $32.0M | ||
| Q2 24 | $-33.4M | $37.0M | ||
| Q1 24 | $-36.0M | $20.0M |
毛利率OFIXTDC
| Q4 25 | 71.1% | 60.8% | ||
| Q3 25 | 72.2% | 60.8% | ||
| Q2 25 | 68.7% | 56.4% | ||
| Q1 25 | 62.8% | 59.3% | ||
| Q4 24 | 69.0% | 59.4% | ||
| Q3 24 | 68.7% | 60.5% | ||
| Q2 24 | 67.8% | 60.8% | ||
| Q1 24 | 67.5% | 61.1% |
营业利润率OFIXTDC
| Q4 25 | 0.2% | 12.8% | ||
| Q3 25 | -8.3% | 14.7% | ||
| Q2 25 | -7.9% | 5.9% | ||
| Q1 25 | -25.2% | 15.8% | ||
| Q4 24 | -5.3% | 9.5% | ||
| Q3 24 | -9.6% | 12.7% | ||
| Q2 24 | -12.5% | 15.1% | ||
| Q1 24 | -15.6% | 10.3% |
净利率OFIXTDC
| Q4 25 | -1.0% | 8.8% | ||
| Q3 25 | -11.1% | 9.6% | ||
| Q2 25 | -6.9% | 2.2% | ||
| Q1 25 | -27.4% | 10.5% | ||
| Q4 24 | -13.5% | 6.1% | ||
| Q3 24 | -13.9% | 7.3% | ||
| Q2 24 | -16.8% | 8.5% | ||
| Q1 24 | -19.1% | 4.3% |
每股收益（稀释后）OFIXTDC
| Q4 25 | $-0.05 | $0.39 | ||
| Q3 25 | $-0.57 | $0.42 | ||
| Q2 25 | $-0.36 | $0.09 | ||
| Q1 25 | $-1.35 | $0.45 | ||
| Q4 24 | $-0.76 | $0.25 | ||
| Q3 24 | $-0.71 | $0.33 | ||
| Q2 24 | $-0.88 | $0.38 | ||
| Q1 24 | $-0.95 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $493.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $230.0M |
| 总资产 | $850.6M | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXTDC
| Q4 25 | $82.0M | $493.0M | ||
| Q3 25 | $62.9M | $406.0M | ||
| Q2 25 | $65.6M | $369.0M | ||
| Q1 25 | $58.0M | $368.0M | ||
| Q4 24 | $83.2M | $420.0M | ||
| Q3 24 | $30.1M | $348.0M | ||
| Q2 24 | $26.4M | $301.0M | ||
| Q1 24 | $27.0M | $337.0M |
总债务OFIXTDC
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXTDC
| Q4 25 | $450.0M | $230.0M | ||
| Q3 25 | $442.5M | $219.0M | ||
| Q2 25 | $458.3M | $176.0M | ||
| Q1 25 | $458.3M | $158.0M | ||
| Q4 24 | $503.1M | $133.0M | ||
| Q3 24 | $525.9M | $125.0M | ||
| Q2 24 | $546.0M | $75.0M | ||
| Q1 24 | $570.3M | $54.0M |
总资产OFIXTDC
| Q4 25 | $850.6M | $1.8B | ||
| Q3 25 | $832.6M | $1.8B | ||
| Q2 25 | $837.2M | $1.7B | ||
| Q1 25 | $823.1M | $1.8B | ||
| Q4 24 | $893.3M | $1.7B | ||
| Q3 24 | $867.9M | $1.7B | ||
| Q2 24 | $882.0M | $1.6B | ||
| Q1 24 | $906.0M | $1.7B |
负债/权益比OFIXTDC
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $160.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $151.0M |
| 自由现金流率自由现金流/营收 | 7.6% | 35.9% |
| 资本支出强度资本支出/营收 | 4.9% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 4.32× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $286.0M |
8季度趋势，按日历期对齐
经营现金流OFIXTDC
| Q4 25 | $27.7M | $160.0M | ||
| Q3 25 | $12.4M | $94.0M | ||
| Q2 25 | $11.6M | $43.0M | ||
| Q1 25 | $-18.4M | $8.0M | ||
| Q4 24 | $23.7M | $156.0M | ||
| Q3 24 | $11.7M | $77.0M | ||
| Q2 24 | $9.0M | $43.0M | ||
| Q1 24 | $-18.6M | $27.0M |
自由现金流OFIXTDC
| Q4 25 | $16.8M | $151.0M | ||
| Q3 25 | $2.5M | $89.0M | ||
| Q2 25 | $4.5M | $39.0M | ||
| Q1 25 | $-25.1M | $7.0M | ||
| Q4 24 | $15.2M | $149.0M | ||
| Q3 24 | $6.3M | $69.0M | ||
| Q2 24 | $-360.0K | $40.0M | ||
| Q1 24 | $-29.1M | $21.0M |
自由现金流率OFIXTDC
| Q4 25 | 7.6% | 35.9% | ||
| Q3 25 | 1.2% | 21.4% | ||
| Q2 25 | 2.2% | 9.6% | ||
| Q1 25 | -13.0% | 1.7% | ||
| Q4 24 | 7.0% | 36.4% | ||
| Q3 24 | 3.2% | 15.7% | ||
| Q2 24 | -0.2% | 9.2% | ||
| Q1 24 | -15.4% | 4.5% |
资本支出强度OFIXTDC
| Q4 25 | 4.9% | 2.1% | ||
| Q3 25 | 4.8% | 1.2% | ||
| Q2 25 | 3.5% | 1.0% | ||
| Q1 25 | 3.5% | 0.2% | ||
| Q4 24 | 4.0% | 1.7% | ||
| Q3 24 | 2.7% | 1.8% | ||
| Q2 24 | 4.7% | 0.7% | ||
| Q1 24 | 5.6% | 1.3% |
现金转化率OFIXTDC
| Q4 25 | — | 4.32× | ||
| Q3 25 | — | 2.35× | ||
| Q2 25 | — | 4.78× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 6.24× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | — | 1.16× | ||
| Q1 24 | — | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
TDC
| Services And Other Recurring | $302.0M | 72% |
| Subscription Software License Recurring | $65.0M | 15% |
| Consulting Services Segment | $53.0M | 13% |
| Software And Hardware Perpetual | $1.0M | 0% |
